Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of nivolumab for sepsis-induced immunosuppression in chronically critically ill patients
ChiCTR2600135383Phase 2Not yet recruiting
- Sponsor
- Shenzhen People's Hospital
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nivolumab in sepsis and ventilator dependence (PMV) (2 arms), sponsored by Shenzhen People's Hospital. Primary endpoint: 28-day organ failure-free survival. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
03
Conditions
sepsisventilator dependence (PMV)
Beyond the preview
Go deeper on ChiCTR2600135383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135383.